Aktienanalyse zu Cytosorbents Corp (CTSO)CTSOCytosorbents Corp

CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Cytosorbents Corp (CTSO) is not a good buy right now due to its current price of $0.3356, which is down 9.30% over the past five days, and a concerning RSI of 38.42 indicating potential oversold conditions. The company reported a significant earnings miss with a net income loss of $4.4 million in Q2 2026, which reflects ongoing profitability challenges. Additionally, the forward P/E ratio of 7.20 suggests that while the stock may be undervalued, the risks associated with its financial instability and negative market sentiment outweigh potential rewards at this time.

4 analysts cover CTSO: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 0.75.